| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antibodies, Viral | 42 | 2026 | 341 | 6.720 |
Why?
|
| Antibodies, Neutralizing | 31 | 2026 | 175 | 5.950 |
Why?
|
| Influenza, Human | 22 | 2026 | 357 | 5.850 |
Why?
|
| Influenza Vaccines | 19 | 2026 | 176 | 5.590 |
Why?
|
| HIV-1 | 17 | 2024 | 180 | 4.730 |
Why?
|
| HIV Antibodies | 15 | 2024 | 40 | 4.350 |
Why?
|
| Nanoparticles | 20 | 2026 | 218 | 4.290 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 15 | 2020 | 42 | 4.100 |
Why?
|
| HIV Infections | 20 | 2024 | 1018 | 2.940 |
Why?
|
| Peptides | 14 | 2025 | 671 | 2.860 |
Why?
|
| Polyethylene Glycols | 15 | 2026 | 383 | 2.810 |
Why?
|
| Orthomyxoviridae | 6 | 2024 | 46 | 2.650 |
Why?
|
| Orthomyxoviridae Infections | 8 | 2022 | 59 | 2.400 |
Why?
|
| Proteins | 8 | 2026 | 804 | 2.330 |
Why?
|
| Phagocytosis | 8 | 2024 | 118 | 2.140 |
Why?
|
| Crystallography, X-Ray | 16 | 2026 | 531 | 2.040 |
Why?
|
| Antibody Formation | 8 | 2025 | 173 | 1.560 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 3 | 2019 | 23 | 1.530 |
Why?
|
| Simian Immunodeficiency Virus | 3 | 2018 | 22 | 1.520 |
Why?
|
| Receptors, Fc | 6 | 2022 | 38 | 1.500 |
Why?
|
| Immunoglobulin Fc Fragments | 4 | 2020 | 30 | 1.470 |
Why?
|
| Lymphocyte Activation | 10 | 2025 | 822 | 1.460 |
Why?
|
| Receptors, IgG | 11 | 2025 | 70 | 1.430 |
Why?
|
| Cnidarian Venoms | 3 | 2017 | 19 | 1.410 |
Why?
|
| Immunogenicity, Vaccine | 5 | 2026 | 22 | 1.390 |
Why?
|
| Models, Molecular | 12 | 2026 | 1396 | 1.380 |
Why?
|
| Polymers | 9 | 2026 | 224 | 1.360 |
Why?
|
| Solid-Phase Synthesis Techniques | 5 | 2025 | 7 | 1.330 |
Why?
|
| Killer Cells, Natural | 8 | 2023 | 297 | 1.320 |
Why?
|
| Liposomes | 9 | 2026 | 104 | 1.250 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 10 | 2024 | 85 | 1.180 |
Why?
|
| CD8-Positive T-Lymphocytes | 15 | 2025 | 701 | 1.170 |
Why?
|
| Amino Acid Sequence | 17 | 2021 | 2008 | 1.150 |
Why?
|
| Humans | 117 | 2026 | 98363 | 1.110 |
Why?
|
| Esters | 4 | 2016 | 31 | 1.080 |
Why?
|
| Animals | 54 | 2026 | 28981 | 1.040 |
Why?
|
| Lipids | 6 | 2026 | 295 | 1.020 |
Why?
|
| Stereoisomerism | 10 | 2026 | 102 | 1.020 |
Why?
|
| B-Lymphocytes | 12 | 2026 | 731 | 0.990 |
Why?
|
| Semen | 3 | 2021 | 19 | 0.980 |
Why?
|
| Insulin | 4 | 2016 | 1224 | 0.960 |
Why?
|
| Drug Delivery Systems | 4 | 2026 | 202 | 0.940 |
Why?
|
| CD4-Positive T-Lymphocytes | 9 | 2025 | 506 | 0.910 |
Why?
|
| Spike Glycoprotein, Coronavirus | 14 | 2026 | 67 | 0.910 |
Why?
|
| Vaccination | 16 | 2026 | 326 | 0.910 |
Why?
|
| Sea Anemones | 2 | 2017 | 18 | 0.900 |
Why?
|
| Scorpion Venoms | 2 | 2016 | 25 | 0.900 |
Why?
|
| Green Chemistry Technology | 1 | 2025 | 4 | 0.890 |
Why?
|
| Macaca nemestrina | 5 | 2020 | 24 | 0.880 |
Why?
|
| AIDS Vaccines | 5 | 2022 | 16 | 0.880 |
Why?
|
| Protein Conformation | 8 | 2026 | 931 | 0.880 |
Why?
|
| Sulfhydryl Compounds | 2 | 2017 | 67 | 0.860 |
Why?
|
| Chemokine CCL1 | 2 | 2014 | 4 | 0.830 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 8 | 2021 | 150 | 0.810 |
Why?
|
| Influenza Pandemic, 1918-1919 | 1 | 2023 | 1 | 0.810 |
Why?
|
| Protein Corona | 2 | 2020 | 2 | 0.810 |
Why?
|
| Receptors, Antigen, T-Cell | 6 | 2025 | 453 | 0.810 |
Why?
|
| Protein Folding | 6 | 2017 | 291 | 0.800 |
Why?
|
| Doxorubicin | 1 | 2024 | 285 | 0.790 |
Why?
|
| Serine | 2 | 2014 | 106 | 0.790 |
Why?
|
| Hemagglutination Inhibition Tests | 7 | 2025 | 44 | 0.790 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2024 | 150 | 0.780 |
Why?
|
| Influenza A virus | 6 | 2026 | 177 | 0.780 |
Why?
|
| Immunization, Secondary | 2 | 2025 | 42 | 0.750 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 112 | 0.750 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 7 | 2025 | 116 | 0.750 |
Why?
|
| Immunoglobulin G | 13 | 2025 | 480 | 0.740 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2025 | 373 | 0.730 |
Why?
|
| HIV Protease | 2 | 2012 | 10 | 0.720 |
Why?
|
| Mucosal-Associated Invariant T Cells | 2 | 2019 | 14 | 0.720 |
Why?
|
| Cytokines | 9 | 2026 | 891 | 0.710 |
Why?
|
| RNA, Messenger | 8 | 2026 | 2070 | 0.690 |
Why?
|
| Molecular Sequence Data | 11 | 2016 | 2897 | 0.690 |
Why?
|
| Immunity, Humoral | 4 | 2023 | 76 | 0.670 |
Why?
|
| Viral Proteins | 3 | 2025 | 252 | 0.670 |
Why?
|
| T-Lymphocytes | 7 | 2026 | 1334 | 0.670 |
Why?
|
| Chemistry Techniques, Synthetic | 2 | 2018 | 9 | 0.640 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2021 | 402 | 0.630 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 2 | 2018 | 29 | 0.620 |
Why?
|
| Adjuvants, Immunologic | 2 | 2023 | 177 | 0.620 |
Why?
|
| Vaccines, Inactivated | 6 | 2025 | 32 | 0.610 |
Why?
|
| Virus Activation | 2 | 2017 | 37 | 0.580 |
Why?
|
| Integrins | 1 | 2019 | 83 | 0.570 |
Why?
|
| Monocytes | 2 | 2019 | 220 | 0.560 |
Why?
|
| Carbon Isotopes | 2 | 2016 | 59 | 0.560 |
Why?
|
| Antibodies, Bispecific | 1 | 2019 | 51 | 0.550 |
Why?
|
| Male | 33 | 2025 | 47257 | 0.550 |
Why?
|
| Recombinant Proteins | 5 | 2019 | 994 | 0.530 |
Why?
|
| Disease Transmission, Infectious | 1 | 2018 | 56 | 0.530 |
Why?
|
| Glycoproteins | 1 | 2018 | 222 | 0.530 |
Why?
|
| Threonine | 1 | 2017 | 32 | 0.500 |
Why?
|
| Insulin Lispro | 1 | 2017 | 4 | 0.500 |
Why?
|
| Isoleucine | 1 | 2017 | 18 | 0.500 |
Why?
|
| Influenza B virus | 3 | 2026 | 36 | 0.500 |
Why?
|
| Hydrofluoric Acid | 1 | 2016 | 5 | 0.500 |
Why?
|
| Adaptive Immunity | 2 | 2021 | 194 | 0.500 |
Why?
|
| Crystallization | 4 | 2026 | 219 | 0.490 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2016 | 24 | 0.490 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2016 | 35 | 0.490 |
Why?
|
| Immunity | 3 | 2023 | 161 | 0.480 |
Why?
|
| Immunoglobulins, Intravenous | 4 | 2023 | 67 | 0.480 |
Why?
|
| Epitopes | 5 | 2021 | 259 | 0.480 |
Why?
|
| Macaca | 4 | 2021 | 83 | 0.480 |
Why?
|
| Fluorescent Dyes | 2 | 2016 | 257 | 0.480 |
Why?
|
| Oxygen Isotopes | 1 | 2016 | 17 | 0.470 |
Why?
|
| Germinal Center | 3 | 2021 | 69 | 0.450 |
Why?
|
| Female | 32 | 2026 | 51756 | 0.440 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 4 | 2019 | 10 | 0.440 |
Why?
|
| Chemistry, Analytic | 1 | 2015 | 2 | 0.440 |
Why?
|
| Peptidomimetics | 1 | 2015 | 3 | 0.440 |
Why?
|
| Receptors, Cell Surface | 1 | 2016 | 291 | 0.440 |
Why?
|
| Erythropoietin | 2 | 2013 | 90 | 0.440 |
Why?
|
| Biological Science Disciplines | 1 | 2015 | 14 | 0.440 |
Why?
|
| Adult | 21 | 2025 | 29587 | 0.430 |
Why?
|
| Immunologic Memory | 6 | 2024 | 189 | 0.430 |
Why?
|
| Synthetic Biology | 1 | 2014 | 17 | 0.430 |
Why?
|
| Mucous Membrane | 1 | 2014 | 83 | 0.420 |
Why?
|
| Testis | 1 | 2015 | 149 | 0.420 |
Why?
|
| Antibodies | 3 | 2026 | 349 | 0.410 |
Why?
|
| Middle Aged | 22 | 2025 | 29532 | 0.410 |
Why?
|
| Australia | 7 | 2023 | 126 | 0.410 |
Why?
|
| Cross Reactions | 4 | 2024 | 116 | 0.400 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 416 | 0.390 |
Why?
|
| Mass Spectrometry | 6 | 2016 | 189 | 0.390 |
Why?
|
| Sulfoxides | 2 | 2025 | 8 | 0.390 |
Why?
|
| Mice | 18 | 2026 | 12735 | 0.390 |
Why?
|
| Mercaptoethanol | 1 | 2013 | 7 | 0.380 |
Why?
|
| Carboxylic Acids | 1 | 2013 | 16 | 0.380 |
Why?
|
| Immunization, Passive | 3 | 2023 | 69 | 0.380 |
Why?
|
| Aspartic Acid | 1 | 2012 | 62 | 0.360 |
Why?
|
| Protein Binding | 6 | 2021 | 1561 | 0.360 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2015 | 403 | 0.360 |
Why?
|
| Biocatalysis | 1 | 2012 | 55 | 0.360 |
Why?
|
| Crystallography | 1 | 2012 | 46 | 0.360 |
Why?
|
| Vaccines, Synthetic | 3 | 2024 | 61 | 0.350 |
Why?
|
| Immunodominant Epitopes | 2 | 2021 | 26 | 0.340 |
Why?
|
| Epitopes, T-Lymphocyte | 5 | 2024 | 99 | 0.340 |
Why?
|
| Hemagglutinins | 3 | 2022 | 22 | 0.340 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 341 | 0.340 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 337 | 0.330 |
Why?
|
| HLA-A2 Antigen | 2 | 2021 | 32 | 0.330 |
Why?
|
| Plant Proteins | 1 | 2011 | 131 | 0.330 |
Why?
|
| Aged | 12 | 2025 | 21844 | 0.330 |
Why?
|
| Proline | 1 | 2010 | 51 | 0.330 |
Why?
|
| Micelles | 2 | 2021 | 57 | 0.320 |
Why?
|
| Hematologic Neoplasms | 2 | 2025 | 383 | 0.320 |
Why?
|
| Protein Structure, Tertiary | 4 | 2017 | 733 | 0.310 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 2017 | 307 | 0.310 |
Why?
|
| Viremia | 3 | 2019 | 56 | 0.310 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2009 | 8 | 0.310 |
Why?
|
| Proinsulin | 1 | 2010 | 123 | 0.310 |
Why?
|
| Glycopeptides | 1 | 2009 | 18 | 0.310 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2023 | 291 | 0.300 |
Why?
|
| Tissue Distribution | 3 | 2026 | 290 | 0.300 |
Why?
|
| Immunoassay | 2 | 2020 | 102 | 0.280 |
Why?
|
| Viral Vaccines | 2 | 2020 | 38 | 0.280 |
Why?
|
| Anti-Retroviral Agents | 2 | 2019 | 36 | 0.280 |
Why?
|
| Disease Models, Animal | 4 | 2020 | 2577 | 0.270 |
Why?
|
| Antibodies, Monoclonal | 6 | 2021 | 1419 | 0.270 |
Why?
|
| Cell Line | 4 | 2016 | 2483 | 0.260 |
Why?
|
| Granulocytes | 2 | 2019 | 34 | 0.260 |
Why?
|
| Betacoronavirus | 2 | 2020 | 286 | 0.260 |
Why?
|
| Hydroxamic Acids | 2 | 2017 | 53 | 0.250 |
Why?
|
| Nanomedicine | 1 | 2026 | 19 | 0.240 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2017 | 218 | 0.240 |
Why?
|
| Binding Sites | 4 | 2021 | 1160 | 0.240 |
Why?
|
| Disease Progression | 2 | 2024 | 1615 | 0.230 |
Why?
|
| Neuraminidase | 1 | 2025 | 46 | 0.230 |
Why?
|
| Plasma | 1 | 2025 | 49 | 0.230 |
Why?
|
| Serum | 1 | 2025 | 26 | 0.230 |
Why?
|
| Kv1.3 Potassium Channel | 2 | 2017 | 13 | 0.230 |
Why?
|
| Serologic Tests | 1 | 2025 | 42 | 0.230 |
Why?
|
| Molecular Structure | 3 | 2020 | 304 | 0.230 |
Why?
|
| Interferons | 1 | 2026 | 114 | 0.230 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 3 | 2023 | 119 | 0.220 |
Why?
|
| Cells, Cultured | 3 | 2021 | 2858 | 0.220 |
Why?
|
| Nucleoproteins | 2 | 2022 | 20 | 0.220 |
Why?
|
| Indoles | 2 | 2017 | 337 | 0.220 |
Why?
|
| Phenotype | 7 | 2024 | 2667 | 0.220 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 2 | 2017 | 65 | 0.220 |
Why?
|
| Young Adult | 8 | 2025 | 7568 | 0.210 |
Why?
|
| Hydrolysis | 2 | 2016 | 145 | 0.210 |
Why?
|
| Polymerization | 3 | 2021 | 36 | 0.210 |
Why?
|
| Polysorbates | 2 | 2023 | 2 | 0.210 |
Why?
|
| Isotope Labeling | 2 | 2016 | 54 | 0.210 |
Why?
|
| Squalene | 2 | 2023 | 3 | 0.210 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 2022 | 35 | 0.210 |
Why?
|
| Protein Multimerization | 4 | 2021 | 195 | 0.200 |
Why?
|
| Protein Splicing | 1 | 2023 | 2 | 0.200 |
Why?
|
| Inteins | 1 | 2023 | 3 | 0.200 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 3 | 2025 | 90 | 0.200 |
Why?
|
| Gene Transfer Techniques | 1 | 2024 | 155 | 0.200 |
Why?
|
| Cohort Studies | 4 | 2024 | 3227 | 0.200 |
Why?
|
| Dorsal Raphe Nucleus | 1 | 2023 | 1 | 0.200 |
Why?
|
| Disulfides | 2 | 2017 | 66 | 0.200 |
Why?
|
| Glycosylation | 2 | 2014 | 142 | 0.200 |
Why?
|
| Particle Size | 2 | 2021 | 130 | 0.200 |
Why?
|
| Immunity, Cellular | 3 | 2020 | 187 | 0.200 |
Why?
|
| Fluoxetine | 1 | 2023 | 43 | 0.200 |
Why?
|
| Silicon Dioxide | 2 | 2020 | 40 | 0.190 |
Why?
|
| Ferrets | 2 | 2020 | 50 | 0.190 |
Why?
|
| History, 20th Century | 1 | 2023 | 323 | 0.180 |
Why?
|
| Antigens | 2 | 2023 | 225 | 0.180 |
Why?
|
| Anticoagulants | 1 | 2025 | 484 | 0.180 |
Why?
|
| Vaccines | 1 | 2023 | 86 | 0.170 |
Why?
|
| Pyrogallol | 1 | 2021 | 1 | 0.170 |
Why?
|
| HLA-A24 Antigen | 1 | 2021 | 21 | 0.170 |
Why?
|
| Nanocapsules | 1 | 2021 | 12 | 0.170 |
Why?
|
| Blood | 1 | 2021 | 68 | 0.170 |
Why?
|
| Single-Domain Antibodies | 1 | 2021 | 8 | 0.170 |
Why?
|
| Drug Carriers | 2 | 2025 | 90 | 0.170 |
Why?
|
| Metal-Organic Frameworks | 1 | 2021 | 24 | 0.170 |
Why?
|
| Viral Load | 3 | 2017 | 162 | 0.170 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2021 | 58 | 0.160 |
Why?
|
| Peptide Fragments | 2 | 2020 | 480 | 0.160 |
Why?
|
| Neutrophils | 2 | 2019 | 346 | 0.160 |
Why?
|
| Antigens, Viral | 2 | 2020 | 123 | 0.160 |
Why?
|
| Antibody-Dependent Enhancement | 1 | 2020 | 2 | 0.160 |
Why?
|
| Aging | 1 | 2026 | 770 | 0.160 |
Why?
|
| Kinetics | 3 | 2017 | 1477 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 4 | 2024 | 1110 | 0.160 |
Why?
|
| Nanotechnology | 2 | 2018 | 74 | 0.160 |
Why?
|
| Extinction, Biological | 1 | 2021 | 102 | 0.160 |
Why?
|
| Lung | 3 | 2024 | 1408 | 0.160 |
Why?
|
| Neutralization Tests | 4 | 2021 | 74 | 0.160 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2020 | 7 | 0.160 |
Why?
|
| Retinal Vessels | 1 | 2021 | 54 | 0.160 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily D | 1 | 2020 | 8 | 0.160 |
Why?
|
| Point-of-Care Systems | 1 | 2021 | 155 | 0.160 |
Why?
|
| Ligands | 4 | 2020 | 491 | 0.160 |
Why?
|
| Rectum | 1 | 2021 | 152 | 0.160 |
Why?
|
| Bacteria | 2 | 2017 | 546 | 0.160 |
Why?
|
| Healthy Volunteers | 2 | 2018 | 154 | 0.160 |
Why?
|
| Communicable Diseases | 1 | 2021 | 74 | 0.160 |
Why?
|
| Cysteine | 2 | 2013 | 150 | 0.160 |
Why?
|
| South Australia | 1 | 2020 | 7 | 0.160 |
Why?
|
| Blood Proteins | 1 | 2020 | 147 | 0.160 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 2017 | 43 | 0.160 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2020 | 66 | 0.160 |
Why?
|
| Seminal Plasma Proteins | 1 | 2019 | 2 | 0.150 |
Why?
|
| Protein Stability | 2 | 2017 | 105 | 0.150 |
Why?
|
| Global Health | 1 | 2021 | 215 | 0.150 |
Why?
|
| Molecular Conformation | 2 | 2017 | 112 | 0.150 |
Why?
|
| Butyrophilins | 1 | 2020 | 28 | 0.150 |
Why?
|
| Interleukin-23 | 1 | 2020 | 63 | 0.150 |
Why?
|
| Carrier Proteins | 1 | 2023 | 670 | 0.150 |
Why?
|
| Organosilicon Compounds | 1 | 2019 | 8 | 0.150 |
Why?
|
| Complement System Proteins | 1 | 2020 | 87 | 0.150 |
Why?
|
| Candida albicans | 1 | 2019 | 32 | 0.150 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2019 | 32 | 0.150 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2020 | 106 | 0.150 |
Why?
|
| Lymphocyte Count | 2 | 2021 | 99 | 0.150 |
Why?
|
| Plaque, Amyloid | 1 | 2019 | 69 | 0.150 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2011 | 271 | 0.150 |
Why?
|
| Molecular Dynamics Simulation | 2 | 2012 | 327 | 0.150 |
Why?
|
| Rats | 4 | 2023 | 4074 | 0.150 |
Why?
|
| Virus Diseases | 1 | 2020 | 83 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2019 | 79 | 0.150 |
Why?
|
| Up-Regulation | 2 | 2019 | 743 | 0.140 |
Why?
|
| Amyloid | 1 | 2019 | 104 | 0.140 |
Why?
|
| Cricetulus | 1 | 2019 | 123 | 0.140 |
Why?
|
| CHO Cells | 1 | 2019 | 188 | 0.140 |
Why?
|
| Antifungal Agents | 1 | 2019 | 127 | 0.140 |
Why?
|
| Serotonergic Neurons | 1 | 2018 | 5 | 0.140 |
Why?
|
| Vaccines, DNA | 1 | 2018 | 20 | 0.140 |
Why?
|
| Relaxin | 1 | 2018 | 9 | 0.140 |
Why?
|
| Biotechnology | 1 | 2018 | 30 | 0.140 |
Why?
|
| Circular Dichroism | 3 | 2016 | 118 | 0.140 |
Why?
|
| Leukocyte Common Antigens | 2 | 2016 | 50 | 0.140 |
Why?
|
| Receptors, Chemokine | 1 | 2018 | 30 | 0.140 |
Why?
|
| Proteomics | 1 | 2020 | 280 | 0.140 |
Why?
|
| Raphe Nuclei | 1 | 2018 | 37 | 0.140 |
Why?
|
| Protein Structure, Secondary | 3 | 2017 | 341 | 0.140 |
Why?
|
| Immunoglobulin A | 3 | 2024 | 94 | 0.140 |
Why?
|
| Immunoglobulins | 1 | 2018 | 124 | 0.130 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2015 | 75 | 0.130 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2018 | 114 | 0.130 |
Why?
|
| Bronchi | 1 | 2019 | 229 | 0.130 |
Why?
|
| Phosphorylation | 2 | 2020 | 1145 | 0.130 |
Why?
|
| Human Immunodeficiency Virus Proteins | 1 | 2017 | 4 | 0.130 |
Why?
|
| Single-Chain Antibodies | 1 | 2017 | 21 | 0.130 |
Why?
|
| Antigens, Neoplasm | 1 | 2020 | 365 | 0.130 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2017 | 23 | 0.130 |
Why?
|
| Nanostructures | 1 | 2018 | 93 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 3 | 2023 | 117 | 0.130 |
Why?
|
| Binding Sites, Antibody | 1 | 2017 | 47 | 0.130 |
Why?
|
| Prevalence | 1 | 2021 | 1393 | 0.130 |
Why?
|
| Antifreeze Proteins | 1 | 2017 | 6 | 0.130 |
Why?
|
| Arthropod Proteins | 1 | 2017 | 8 | 0.130 |
Why?
|
| Pandemics | 5 | 2021 | 913 | 0.130 |
Why?
|
| Depsipeptides | 1 | 2017 | 30 | 0.130 |
Why?
|
| Fluorenes | 1 | 2017 | 6 | 0.130 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2017 | 64 | 0.130 |
Why?
|
| Virus Latency | 1 | 2017 | 33 | 0.120 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 3 | 2025 | 105 | 0.120 |
Why?
|
| Immune Tolerance | 1 | 2019 | 386 | 0.120 |
Why?
|
| HIV | 1 | 2017 | 48 | 0.120 |
Why?
|
| Vaccinia virus | 1 | 2016 | 20 | 0.120 |
Why?
|
| Glycine | 1 | 2017 | 96 | 0.120 |
Why?
|
| Dendritic Cells | 2 | 2026 | 552 | 0.120 |
Why?
|
| NAV1.4 Voltage-Gated Sodium Channel | 1 | 2016 | 3 | 0.120 |
Why?
|
| Scorpions | 1 | 2016 | 6 | 0.120 |
Why?
|
| Immunologic Techniques | 1 | 2016 | 25 | 0.120 |
Why?
|
| Immune Sera | 1 | 2016 | 48 | 0.120 |
Why?
|
| Molecular Docking Simulation | 1 | 2016 | 59 | 0.120 |
Why?
|
| Virus Shedding | 1 | 2016 | 20 | 0.120 |
Why?
|
| Immobilized Proteins | 1 | 2016 | 15 | 0.120 |
Why?
|
| Cross Protection | 1 | 2016 | 11 | 0.120 |
Why?
|
| Caveolin 1 | 1 | 2016 | 24 | 0.120 |
Why?
|
| Stem Cells | 1 | 2019 | 397 | 0.120 |
Why?
|
| Microspheres | 1 | 2016 | 97 | 0.120 |
Why?
|
| Cattle | 1 | 2016 | 397 | 0.120 |
Why?
|
| Adenine | 1 | 2016 | 101 | 0.120 |
Why?
|
| ErbB Receptors | 1 | 2019 | 517 | 0.120 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 2896 | 0.120 |
Why?
|
| RNA, Viral | 3 | 2023 | 288 | 0.120 |
Why?
|
| Anxiety | 1 | 2018 | 370 | 0.110 |
Why?
|
| Cell Survival | 1 | 2017 | 1017 | 0.110 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 427 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 1 | 2018 | 526 | 0.110 |
Why?
|
| Hydrogen Bonding | 2 | 2017 | 160 | 0.110 |
Why?
|
| Seminiferous Tubules | 1 | 2015 | 8 | 0.110 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2016 | 321 | 0.110 |
Why?
|
| Macrophages | 2 | 2019 | 643 | 0.110 |
Why?
|
| Receptors, CCR6 | 1 | 2014 | 4 | 0.110 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2014 | 5 | 0.110 |
Why?
|
| Vaccines, Subunit | 1 | 2015 | 54 | 0.110 |
Why?
|
| Enzymes | 1 | 2015 | 47 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 4 | 2026 | 3616 | 0.110 |
Why?
|
| Catalysis | 1 | 2015 | 216 | 0.110 |
Why?
|
| Lymphocyte Subsets | 1 | 2014 | 72 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 2017 | 0.100 |
Why?
|
| Case-Control Studies | 2 | 2016 | 2009 | 0.100 |
Why?
|
| Anti-HIV Agents | 1 | 2017 | 211 | 0.100 |
Why?
|
| Chromatography, Liquid | 1 | 2014 | 102 | 0.100 |
Why?
|
| Adolescent | 4 | 2023 | 10137 | 0.100 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 845 | 0.100 |
Why?
|
| Computer Simulation | 1 | 2018 | 1147 | 0.100 |
Why?
|
| Alzheimer Disease | 1 | 2019 | 649 | 0.100 |
Why?
|
| Epoetin Alfa | 1 | 2013 | 2 | 0.100 |
Why?
|
| Isoelectric Focusing | 1 | 2013 | 28 | 0.100 |
Why?
|
| Carbohydrate Sequence | 1 | 2013 | 18 | 0.100 |
Why?
|
| Forecasting | 1 | 2015 | 297 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 1 | 2018 | 448 | 0.100 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2014 | 214 | 0.100 |
Why?
|
| Polysaccharides | 1 | 2013 | 100 | 0.090 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2015 | 214 | 0.090 |
Why?
|
| Action Potentials | 1 | 2016 | 611 | 0.090 |
Why?
|
| HEK293 Cells | 1 | 2015 | 719 | 0.090 |
Why?
|
| Multiprotein Complexes | 1 | 2012 | 106 | 0.090 |
Why?
|
| Cricetinae | 2 | 2023 | 533 | 0.090 |
Why?
|
| Bacterial Proteins | 2 | 2015 | 901 | 0.090 |
Why?
|
| Surface Plasmon Resonance | 3 | 2017 | 49 | 0.090 |
Why?
|
| Substrate Specificity | 1 | 2012 | 374 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2014 | 988 | 0.080 |
Why?
|
| Models, Biological | 1 | 2018 | 1805 | 0.080 |
Why?
|
| Dimerization | 1 | 2011 | 149 | 0.080 |
Why?
|
| Models, Chemical | 1 | 2011 | 186 | 0.080 |
Why?
|
| Time Factors | 2 | 2017 | 5576 | 0.080 |
Why?
|
| Amino Acid Substitution | 1 | 2011 | 335 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 7418 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 523 | 0.080 |
Why?
|
| Escherichia coli | 3 | 2019 | 572 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2023 | 9770 | 0.080 |
Why?
|
| Biomarkers | 3 | 2025 | 2021 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 2381 | 0.080 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2011 | 340 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 2023 | 0.070 |
Why?
|
| Immunophenotyping | 2 | 2020 | 228 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2020 | 213 | 0.070 |
Why?
|
| Flow Cytometry | 2 | 2021 | 722 | 0.060 |
Why?
|
| Antigens, CD | 2 | 2020 | 484 | 0.060 |
Why?
|
| Phosphatidylethanolamines | 1 | 2025 | 18 | 0.060 |
Why?
|
| Methacrylates | 1 | 2025 | 10 | 0.060 |
Why?
|
| Antigens, Differentiation | 1 | 2026 | 126 | 0.060 |
Why?
|
| Neoplasms | 1 | 2021 | 3348 | 0.050 |
Why?
|
| Receptors, CXCR4 | 1 | 2025 | 50 | 0.050 |
Why?
|
| Saliva | 1 | 2025 | 134 | 0.050 |
Why?
|
| Administration, Intranasal | 1 | 2024 | 141 | 0.050 |
Why?
|
| Immunity, Mucosal | 1 | 2024 | 71 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2025 | 471 | 0.050 |
Why?
|
| Transfection | 1 | 2025 | 883 | 0.050 |
Why?
|
| Extinction, Psychological | 1 | 2023 | 22 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2024 | 225 | 0.050 |
Why?
|
| Ferritins | 1 | 2023 | 28 | 0.050 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily C | 1 | 2022 | 10 | 0.050 |
Why?
|
| Protein Subunits | 1 | 2023 | 121 | 0.050 |
Why?
|
| Fear | 1 | 2023 | 91 | 0.050 |
Why?
|
| Macaca fascicularis | 1 | 2022 | 111 | 0.050 |
Why?
|
| Retrospective Studies | 1 | 2017 | 11039 | 0.050 |
Why?
|
| Virion | 1 | 2022 | 62 | 0.050 |
Why?
|
| RNA Splicing | 1 | 2023 | 163 | 0.040 |
Why?
|
| Mass Vaccination | 1 | 2021 | 10 | 0.040 |
Why?
|
| RAW 264.7 Cells | 1 | 2021 | 21 | 0.040 |
Why?
|
| Receptors, Virus | 1 | 2021 | 74 | 0.040 |
Why?
|
| Camelids, New World | 1 | 2021 | 4 | 0.040 |
Why?
|
| Oxazines | 1 | 2021 | 16 | 0.040 |
Why?
|
| Oxazoles | 1 | 2021 | 14 | 0.040 |
Why?
|
| Immune Evasion | 1 | 2021 | 37 | 0.040 |
Why?
|
| Convalescence | 1 | 2021 | 10 | 0.040 |
Why?
|
| Metal Nanoparticles | 1 | 2021 | 37 | 0.040 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2021 | 18 | 0.040 |
Why?
|
| Age Factors | 1 | 2026 | 1974 | 0.040 |
Why?
|
| Receptors, CXCR3 | 1 | 2021 | 13 | 0.040 |
Why?
|
| Gold | 1 | 2021 | 45 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2021 | 27 | 0.040 |
Why?
|
| Amino Acid Motifs | 1 | 2021 | 118 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 1 | 2021 | 65 | 0.040 |
Why?
|
| Acute Disease | 1 | 2023 | 860 | 0.040 |
Why?
|
| Peptide Library | 1 | 2021 | 87 | 0.040 |
Why?
|
| Polyproteins | 1 | 2020 | 4 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2021 | 111 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 154 | 0.040 |
Why?
|
| Respiratory Tract Diseases | 1 | 2020 | 45 | 0.040 |
Why?
|
| Eye | 1 | 2021 | 112 | 0.040 |
Why?
|
| Cryoelectron Microscopy | 1 | 2021 | 143 | 0.040 |
Why?
|
| Vero Cells | 1 | 2020 | 100 | 0.040 |
Why?
|
| Models, Immunological | 1 | 2020 | 86 | 0.040 |
Why?
|
| Halogenation | 1 | 2020 | 9 | 0.040 |
Why?
|
| Fluorine | 1 | 2020 | 11 | 0.040 |
Why?
|
| Risk | 1 | 2021 | 660 | 0.040 |
Why?
|
| Rabbits | 1 | 2021 | 582 | 0.040 |
Why?
|
| Microvessels | 1 | 2020 | 70 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2021 | 173 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2021 | 264 | 0.040 |
Why?
|
| Bevacizumab | 1 | 2021 | 255 | 0.040 |
Why?
|
| Safety | 1 | 2020 | 138 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2021 | 283 | 0.040 |
Why?
|
| Respiratory Burst | 1 | 2019 | 19 | 0.040 |
Why?
|
| Madin Darby Canine Kidney Cells | 1 | 2019 | 23 | 0.040 |
Why?
|
| Candidiasis | 1 | 2019 | 40 | 0.040 |
Why?
|
| Viral Core Proteins | 1 | 2019 | 24 | 0.040 |
Why?
|
| Solubility | 1 | 2020 | 187 | 0.040 |
Why?
|
| Child | 2 | 2021 | 7745 | 0.040 |
Why?
|
| HIV Seropositivity | 1 | 2019 | 49 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2019 | 65 | 0.040 |
Why?
|
| Protein Domains | 1 | 2020 | 170 | 0.040 |
Why?
|
| Haplorhini | 1 | 2019 | 77 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2020 | 945 | 0.040 |
Why?
|
| Injections, Intradermal | 1 | 2018 | 19 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2018 | 63 | 0.040 |
Why?
|
| Microglia | 1 | 2019 | 131 | 0.030 |
Why?
|
| Swine Diseases | 1 | 2018 | 15 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2021 | 1255 | 0.030 |
Why?
|
| Interferon-gamma Release Tests | 1 | 2018 | 2 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2020 | 557 | 0.030 |
Why?
|
| Electroporation | 1 | 2018 | 61 | 0.030 |
Why?
|
| Antibody-Producing Cells | 1 | 2018 | 13 | 0.030 |
Why?
|
| Dogs | 1 | 2019 | 642 | 0.030 |
Why?
|
| Water | 1 | 2020 | 309 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2022 | 1607 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 2018 | 103 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 2056 | 0.030 |
Why?
|
| Protein Transport | 1 | 2019 | 447 | 0.030 |
Why?
|
| Prosencephalon | 1 | 2018 | 70 | 0.030 |
Why?
|
| Amyloid beta-Peptides | 1 | 2019 | 251 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2018 | 304 | 0.030 |
Why?
|
| HIV Long-Term Survivors | 1 | 2017 | 2 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2018 | 174 | 0.030 |
Why?
|
| DNA Primers | 1 | 2018 | 530 | 0.030 |
Why?
|
| Caffeine | 1 | 2018 | 86 | 0.030 |
Why?
|
| Proof of Concept Study | 1 | 2017 | 64 | 0.030 |
Why?
|
| Siphonaptera | 1 | 2017 | 8 | 0.030 |
Why?
|
| Genome | 1 | 2020 | 417 | 0.030 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2020 | 206 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2021 | 482 | 0.030 |
Why?
|
| Swine | 1 | 2018 | 593 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2017 | 87 | 0.030 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2016 | 19 | 0.030 |
Why?
|
| Base Sequence | 1 | 2020 | 2224 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2022 | 2212 | 0.030 |
Why?
|
| Perforin | 1 | 2016 | 56 | 0.030 |
Why?
|
| Granzymes | 1 | 2016 | 96 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2020 | 746 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2017 | 403 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 135 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2017 | 353 | 0.030 |
Why?
|
| Antigen-Antibody Complex | 1 | 2016 | 89 | 0.030 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2016 | 37 | 0.030 |
Why?
|
| Thermodynamics | 1 | 2017 | 327 | 0.030 |
Why?
|
| Calibration | 1 | 2016 | 109 | 0.030 |
Why?
|
| Virus Replication | 1 | 2017 | 292 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 970 | 0.030 |
Why?
|
| Reference Standards | 1 | 2016 | 147 | 0.030 |
Why?
|
| Pregnancy | 1 | 2023 | 3269 | 0.030 |
Why?
|
| Thermus | 1 | 2015 | 5 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2016 | 285 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2021 | 904 | 0.030 |
Why?
|
| Phylogeny | 1 | 2021 | 1340 | 0.030 |
Why?
|
| Hospitalization | 1 | 2021 | 988 | 0.030 |
Why?
|
| Ribosomes | 1 | 2015 | 106 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2017 | 509 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2014 | 125 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2021 | 4038 | 0.020 |
Why?
|
| Gene Expression | 1 | 2017 | 1322 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2012 | 18 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 1133 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2012 | 118 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2792 | 0.020 |
Why?
|
| Neurons | 1 | 2019 | 1626 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2016 | 826 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 4428 | 0.020 |
Why?
|
| Risk Factors | 1 | 2020 | 6271 | 0.020 |
Why?
|
| Brain | 1 | 2019 | 2439 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 3612 | 0.020 |
Why?
|